Replimune Group (NASDAQ: REPL) Chief Commercial Officer Christopher Sarchi reported a sale of 6,500 shares of common stock on April 2, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The shares were sold at a weighted average price of $8.01, producing proceeds of $52,065. The transactions occurred in multiple tranches, with execution prices spanning $8.00 to $8.06. The Form 4 filing states the sales were made pursuant to a pre-arranged trading plan that Sarchi adopted on December 15, 2025.
Following the reported disposition, Sarchi still beneficially owns 151,588 shares of Replimune common stock, a total that includes restricted stock units. In addition, he holds options to acquire 250,425 shares, of which 142,555 are presently exercisable.
Market moves since the reported sale show the stock trading at $8.54, representing a 17% uptick over the past week and an 80% increase over the preceding six months. Analysts covering the company are described as maintaining an optimistic stance, with price targets ranging from $10 to $19.
This transaction and the related holdings highlight an executive liquidity event that was executed under a standing plan while leaving Sarchi with meaningful continued equity and option positions. The filing provides a snapshot of a senior officer reducing a portion of his stake within the parameters of an established framework rather than through ad hoc sales.
Context and implications
- The sale was carried out under a pre-arranged trading plan, which typically structures timing and amounts in advance.
- Sarchi retains significant exposure to the company through existing shares, restricted stock units and exercisable options.
- Analyst coverage remains broadly positive based on the disclosed price target range, while the stock has displayed meaningful recent appreciation.
Where the filing offers clear transactional detail, it does not provide further commentary on Sarchi’s motivations beyond the reference to the trading plan. The filing also does not alter the documented holdings and option positions shown in the Form 4.